Longevity Health Holdings Explores Strategic Alternatives for Business

PITTSBURGH, Nov. 11, 2026 /CourierPR/ -- Longevity Health Holdings, Inc., a company focused on longevity and healthy aging, has announced that its Board of Directors is exploring strategic alternatives for the company’s bio-aesthetic and therapeutic businesses. The move comes after the settlement of the Puritan Partners litigation, providing the company with an opportunity to reassess its portfolio and maximize value for its stakeholders.

The company has built a portfolio of regenerative skincare brands and bone and tissue healing therapeutic products, with the latter's development on hold. The Board is committed to pursuing the path that best serves the company and its stakeholders.

The strategic alternatives under consideration include a merger, reverse merger, or other business combination, a sale or license of one or more of the company’s businesses or assets, a strategic partnership, or other transactions. Longevity has not set a timetable for the review and has made no decision to pursue any specific alternative. There can be no assurance that the review will result in any transaction or other outcome.

The company’s forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These include the possibility that the review does not result in any transaction, the terms, timing, structure, and completion of any transaction, the company’s limited cash resources and its ability to continue as a going concern, its ability to obtain additional financing, its obligations under its senior secured convertible notes, including the security interests and the prepayment and default remedies under those notes, and the potential dilution to stockholders.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These include statements about the company’s review of strategic alternatives, the potential transactions the company may evaluate or pursue, the company’s ability to maximize value for its stakeholders, the value of the company’s businesses and assets, and the status and future development of the company’s product pipeline, including its bone and tissue healing products. Words such as “may,” “will,” “intend,” “explore,” “evaluate,” “potential,” “pursue,” “committed,” “maximize,” “believe” and similar expressions identify forward-looking statements. They are based on management’s current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. These include, among others: the possibility that the review does not result in any transaction; the terms, timing, structure and completion of any transaction; the company’s limited cash resources and its ability to continue as a going concern; its ability to obtain additional financing; its obligations under its senior secured convertible notes, including the security interests and the prepayment and default remedies under those notes; the potential dilution to stockholders; the possible diversion of management’s attention; and the other risks described in the company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the quarter ended June 30, 2026. Forward-looking statements speak only as of the date of this release. Except as required by law, the company undertakes no obligation to update them.